KING PHARMACEUTICALS INC - 8-K - 20051104 - DISCLOSURE
Item 7.01
Regulation FD Disclosure.
On
November 1, 2005, King Pharmaceuticals, Inc. issued a issued a press release,
a
copy of which is furnished as Exhibit 99.1, announcing the entering into the
settlement agreements resolving the governmental pricing
investigation.
In
accordance with general instruction B.2 of Form 8-K, this information, including
Exhibit 99.1, shall not be deemed filed for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the
liability of that section, nor shall it be deemed incorporated by reference
in
any filing under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, as amended, except as we may specifically state in any
such filing.
Exhibits:
Exhibit
Number
Description
of Exhibit
10.1
Settlement
Agreement, dated as of October 31, 2005, among the United States
of
America acting through the entities named therein, King Pharmaceuticals,
Inc. and Monarch Pharmaceuticals, Inc.
10.2
Settlement
Agreement, dated as of October 31, 2005, among the state of Massachusetts,
King Pharmaceuticals, Inc. and Monarch Pharmaceuticals, Inc. and
general
description of the other state settlement agreements
10.3
Corporate
Integrity Agreement, dated as of October 31, 2005, between the Office
of
Inspector General of the
Department
of
Health and Human Services and King Pharmaceuticals,
Inc.
99.1
Press
Release
of King Pharmaceuticals, Inc. dated November 1,
2005.
Next Section
Previous Section